Presbyopia
Conditions
Brief summary
Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.
Detailed description
To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.
Interventions
DRUGPilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound
To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
Sponsors
Optall Vision
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
To determine safety and efficacy of a Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac compound to improve near uncorrected vision in healthy presbyopic patients
Eligibility
Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy * Presbyopic * 40 - 60 years
Exclusion criteria
* Diabetics * Previous eye surgery * Previous eye disease * \> 0.50 myopia * \> 1.5 hyperopia or astigmatism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Jaeger near uncorrected visual acuity improvement | 1 hour | Measure uncorrected near vision change after binocular instillation of PBOHB compound |
Countries
Mexico
Contacts
Primary ContactCesar Alejandro S Galeana, MD
Backup ContactRosario Perez
Outcome results
None listed